Product Description
A drug used to relieve constipation caused by the use of opioids (pain killers that are like morphine). It is used in adults with pain caused by cancer or treatment for cancer or by other advanced disease. Methylnaltrexone bromide binds to opioid receptors outside the brain and may block the side effects of opioid drugs without affecting their ability to relieve pain. Methylnaltrexone bromide is a type of peripheral opioid receptor antagonist. Also called Relistor. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/methylnaltrexone-bromide)
Mechanisms of Action: OPRM Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Thailand | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Pancreatitis, Acute
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-002313-18 | P3 |
Active, not recruiting |
Pancreatitis, Acute |
2023-10-05 |